Singap Med J 2007;48:1122–4 39 Neri R, Migliorini A, Moschi G,

Singap Med J. 2007;48:1122–4. 39. Neri R, Migliorini A, Moschi G, et al. Percutaneous reperfusion of left main coronary disease Temsirolimus price complicated by acute myocardial infarction. Catheter Cardiovasc Interv. 2002;56:31–4.PubMedCrossRef 40. Valeur N, Gaster AL, Saunamaki K. Percutaneous revascularization in acute myocardial infarction due to left main stem occlusion. Scand Cardiovasc J. 2005;39:24–9.PubMedCrossRef 41. Wang XL, Liu SX, Wilcken DE. Circulating transforming growth factor beta 1 and coronary artery disease. Cardiovasc

Res. 1997;34:404–10.PubMedCrossRef 42. Grainger DJ, Kemp PR, Metcalfe JC, et al. The serum concentration of active transforming growth factor-beta is severely depressed PFT�� in advanced atherosclerosis. Nat Med. 1995;1:74–9.PubMedCrossRef 43. Cipollone F, Fazia M, Mincione G, et al. Increased expression of transforming growth factor-β1 as a stabilizing factor in human atherosclerotic plaques. Stroke. 2004;35:2253–7.PubMedCrossRef 44. Aihara K, Ikeda Y, Yagi S, Akaike M, Matsumoto T. Transforming growth factor-β1 as a common target

molecule for development of cardiovascular diseases, renal insufficiency and metabolic syndrome. Cardiol Res Pract. 2010;2011:175381.PubMed 45. Di Stefano R, Di Bello V, Barsotti MC, et al. Inflammatory markers and cardiac function in acute coronary syndrome: difference in ST-segment elevation myocardial infarction (STEMI) and in non-STEMI models. Biomed Pharmacother. 2009;63:773–80.PubMedCrossRef 46. Smit JJ, Ottervanger JP, Slingerland RJ, On-TIME Study Group,

et al. Comparison of usefulness of C-reactive protein versus white blood cell count to predict outcome after primary percutaneous coronary intervention for ST elevation myocardial infarction. Am J Cardiol. 2008;101:446–51.PubMedCrossRef 47. Walshe TE, Dole VS, Maharaj A, et al. Inhibition of VEGF or TGF-β signaling activates endothelium and increases leukocyte rolling. Arterioscler Thromb Vasc Biol. 2009;29:1185–92.PubMedCrossRef 48. Tanni SE, Pelegrino NR, Angeleli AY, Correa C, Godoy I. Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients. J Inflamm (Lond). 2010;7:29.CrossRef Sorafenib in vitro 49. Diez-Pina JM, Fernandez-Aceñero MJ, Llorente-Alonso MJ, et al. Tumor necrosis factor alpha as a marker of systemic and local inflammation in “healthy” smokers. Int J Gen Med. 2009;2:9–14.PubMedCrossRef 50. Vernooy JH, Küςükaycan M, Jacobs J, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;186:1218–24.CrossRef 51. Gupta-Ganguli M, Cox K, Means B, Gerling I, Solomon SS. Does therapy with anti-TNF-alpha GDC 0449 improve glucose tolerance and control in patients with type 2 diabetes? Diabetes Care. 2011;34:e121.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>